Entrada Therapeutics (TRDA) Stock Overview
A clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
TRDA Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Entrada Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.40 |
| 52 Week High | US$16.45 |
| 52 Week Low | US$4.93 |
| Beta | -0.26 |
| 1 Month Change | 16.17% |
| 3 Month Change | -45.19% |
| 1 Year Change | 9.47% |
| 3 Year Change | -54.21% |
| 5 Year Change | n/a |
| Change since IPO | -69.10% |
Recent News & Updates
Recent updates
New Narrative • May 31
Early Genetic Medicine Pipeline And Cash Runway Will Support Long Term Neuromuscular Opportunity
Catalysts About Entrada Therapeutics Entrada Therapeutics is a clinical stage biopharma company developing proprietary genetic medicines for high unmet need diseases, including neuromuscular and ocular conditions. What are the underlying business or industry changes driving this perspective?
New Narrative • May 14
DMD Franchise And Ocular Pipeline Will Create Multiple Long Term Genetic Medicine Opportunities
Catalysts About Entrada Therapeutics Entrada Therapeutics is a clinical stage biopharma company developing proprietary genetic medicines for high unmet need diseases, with a focus on neuromuscular and ocular disorders. What are the underlying business or industry changes driving this perspective?Analysis Article • Dec 19
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Fly 26% But Investors Aren't Buying For Growth
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shares have continued their recent momentum with a 26% gain in the last...Seeking Alpha • Nov 17
Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts
Summary Entrada Therapeutics reported a 3Q25 GAAP EPS loss of –$1.06 and revenue of $1.6 million, reflecting declining collaboration income. TRDA is heavily investing in its Duchenne muscular dystrophy pipeline, with multiple early-stage clinical programs converging on key data readouts in 2026. Despite widening losses, TRDA maintains a strong cash position of $326.8 million, sufficient to fund operations through 3Q27 and support ongoing R&D. The stock trades at a deep valuation discount due to its large cash balance, but faces amplified risk from clustered 2026 clinical catalysts. Read the full article on Seeking AlphaAnalysis Article • Oct 10
Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 32% But Its Business Still Trails The Industry
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shares have had a really impressive month, gaining 32% after a shaky period...Analysis Article • Aug 09
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) just released its latest second-quarter report and things are not looking...Analysis Article • Apr 04
Lacklustre Performance Is Driving Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) 27% Price Drop
To the annoyance of some shareholders, Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shares are down a considerable 27% in...Analysis Article • Mar 02
Results: Entrada Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
As you might know, Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) just kicked off its latest yearly results with some very...Seeking Alpha • Feb 19
Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside
Summary Entrada Therapeutics addresses intracellular drug delivery challenges with its Endosomal Escape Vehicle platform, positioning itself uniquely in the biotech sector. Strong financials with $449.3 million in reserves and strategic partnerships extend Entrada's runway into 2027, reducing near-term financing risks. ENTR-601-44, targeting Duchenne muscular dystrophy, is entering critical trials, with potential to validate the platform and drive significant market share. Despite scientific and execution risks, successful trials could elevate Entrada's valuation and establish it as a leader in oligonucleotide-based therapies. Read the full article on Seeking AlphaAnalysis Article • Jan 11
The Market Doesn't Like What It Sees From Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Revenues Yet As Shares Tumble 26%
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shares have had a horrible month, losing 26% after a relatively good period...Analysis Article • Oct 17
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding
Entrada Therapeutics, Inc.'s ( NASDAQ:TRDA ) price-to-sales (or "P/S") ratio of 2.6x might make it look like a strong...Analysis Article • Aug 23
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher
Celebrations may be in order for Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shareholders, with the analysts delivering...Seeking Alpha • Jun 16
Entrada Therapeutics: A Complicated Tale
Summary Entrada Therapeutics' stock has dropped significantly due to FDA holds on two IND applications, but recent insider buying suggests potential upside. The company's EEV platform aims to target malady-inducing dysfunction inside cells with high proficiency, potentially revolutionizing treatment across various diseases. Despite ongoing FDA issues, analysts remain optimistic about Entrada's prospects, with a well-padded balance sheet and potential for future collaborations. An analysis around Entrada Therapeutics stock follows in the paragraphs below. Read the full article on Seeking AlphaAnalysis Article • May 29
Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry
The Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) share price has done very well over the last month, posting an excellent...Analysis Article • Mar 19
These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts
One thing we could say about the analysts on Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) - they aren't optimistic...Analysis Article • Nov 09
This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year
Shareholders in Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) may be thrilled to learn that the analysts have just...Analysis Article • May 26
Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shareholders will have a reason to smile today, with the analysts making...Analysis Article • May 14
Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts
Investors in Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) had a good week, as its shares rose 3.1% to close at US$12.50...Analysis Article • Mar 08
Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analysis Article • Sep 11
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Aug 11
Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
Entrada Therapeutics press release (NASDAQ:TRDA): Q2 GAAP EPS of -$0.74 misses by $0.02. Cash, cash equivalents and marketable securities were $244.3 million as of June 30, 2022, compared to $291.1 million as of December 31, 2021.Analysis Article • May 28
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Analysis Article • Jan 31
We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Shareholder Returns
| TRDA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.1% | 3.4% | -0.4% |
| 1Y | 9.5% | 37.9% | 18.4% |
Return vs Industry: TRDA underperformed the US Biotechs industry which returned 37.9% over the past year.
Return vs Market: TRDA underperformed the US Market which returned 18.4% over the past year.
Price Volatility
| TRDA volatility | |
|---|---|
| TRDA Average Weekly Movement | 18.7% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TRDA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TRDA's weekly volatility has increased from 12% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 152 | Dipal Doshi | www.entradatx.com |
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670.
Entrada Therapeutics, Inc. Fundamentals Summary
| TRDA fundamental statistics | |
|---|---|
| Market cap | US$263.77m |
| Earnings (TTM) | -US$166.12m |
| Revenue (TTM) | US$5.74m |
46.5x
P/S Ratio-1.6x
P/E RatioIs TRDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRDA income statement (TTM) | |
|---|---|
| Revenue | US$5.74m |
| Cost of Revenue | US$141.55m |
| Gross Profit | -US$135.81m |
| Other Expenses | US$30.31m |
| Earnings | -US$166.12m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.61 |
| Gross Margin | -2,366.87% |
| Net Profit Margin | -2,895.05% |
| Debt/Equity Ratio | 0% |
How did TRDA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/09 22:26 |
| End of Day Share Price | 2026/07/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Entrada Therapeutics, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ioannis Souroutzidis | Cantor Fitzgerald & Co. |
| Paul Choi | Goldman Sachs |
| Debjit Chattopadhyay | Guggenheim Securities, LLC |